Alsayed et al.   53  reported that the p38 MAPK pathway plays a negative role in the induction of ATRA responses in APL and raises the possibility that combined use of ATRA with pharmacological inhibitors of p38 might be more effective than the use ATRA alone. This evidence concerns the gene MAPK1 and acute promyelocytic leukemia.